310 related articles for article (PubMed ID: 38258058)
1. Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs.
Asano D; Takakusa H; Nakai D
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258058
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
Kim JC; Park EJ; Na DH
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559036
[TBL] [Abstract][Full Text] [Related]
3. Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.
Brayden DJ; Maher S
Expert Opin Drug Deliv; 2021 Oct; 18(10):1501-1512. PubMed ID: 34128734
[TBL] [Abstract][Full Text] [Related]
4. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
Miyasaka K
Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
[TBL] [Abstract][Full Text] [Related]
6. ACTUALITIES IN ENDOCRINE PHARMACOLOGY: ADVANCES IN THE DEVELOPMENT OF ORAL FORMULATIONS FOR CALCITONIN AND SEMAGLUTIDE.
Hamza A; Șaramet G
Acta Endocrinol (Buchar); 2020; 16(3):383-387. PubMed ID: 33363667
[TBL] [Abstract][Full Text] [Related]
7. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
Paquot N
Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
[TBL] [Abstract][Full Text] [Related]
8. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
Tomono T; Yagi H; Ukawa M; Ishizaki S; Miwa T; Nonomura M; Igi R; Kumagai H; Miyata K; Tobita E; Kobayashi H; Sakuma S
Eur J Pharm Biopharm; 2020 Sep; 154():186-194. PubMed ID: 32681963
[TBL] [Abstract][Full Text] [Related]
9. Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs.
Daniel CP; Wagner MJ; Borne GE; Plaisance CJ; Ahmadzadeh S; Aquino A; Shekoohi S; Kaye AM; Cornett EM; Kaye AD
Pathophysiology; 2023 Sep; 30(3):377-388. PubMed ID: 37755395
[TBL] [Abstract][Full Text] [Related]
10. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
[TBL] [Abstract][Full Text] [Related]
11. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
Solis-Herrera C; Kane MP; Triplitt C
Clin Diabetes; 2024; 42(1):74-86. PubMed ID: 38230324
[TBL] [Abstract][Full Text] [Related]
12. Towards the Development of Orally Available Peptide Therapeutics.
Kong XD; Heinis C
Chimia (Aarau); 2021 Jun; 75(6):514-517. PubMed ID: 34233815
[TBL] [Abstract][Full Text] [Related]
13. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
[TBL] [Abstract][Full Text] [Related]
14. A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.
Selvarajan R; Subramanian R
Diabetes Metab Syndr Obes; 2023; 16():1709-1720. PubMed ID: 37312901
[TBL] [Abstract][Full Text] [Related]
15. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery.
Lewis AL; McEntee N; Holland J; Patel A
Drug Deliv Transl Res; 2022 Jan; 12(1):1-6. PubMed ID: 34024013
[TBL] [Abstract][Full Text] [Related]
16. Oral Administration of Peptide-Based Drugs: Beyond Lipinski's Rule.
Santos GB; Ganesan A; Emery FS
ChemMedChem; 2016 Oct; 11(20):2245-2251. PubMed ID: 27596610
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Pharmacokinetics and Systemic Effects of a Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl)amino] Caprylate in Rats.
Chiang PC; Deshmukh G; Liu J; Nagapudi K; Chen JZ; Valle N; Li R; Plise EG; Durk MR
J Pharm Sci; 2020 Aug; 109(8):2629-2636. PubMed ID: 32360544
[TBL] [Abstract][Full Text] [Related]
18. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR; Blonde L; Pratley RE
Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
[TBL] [Abstract][Full Text] [Related]
19. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor.
Tanada M; Tamiya M; Matsuo A; Chiyoda A; Takano K; Ito T; Irie M; Kotake T; Takeyama R; Kawada H; Hayashi R; Ishikawa S; Nomura K; Furuichi N; Morita Y; Kage M; Hashimoto S; Nii K; Sase H; Ohara K; Ohta A; Kuramoto S; Nishimura Y; Iikura H; Shiraishi T
J Am Chem Soc; 2023 Aug; 145(30):16610-16620. PubMed ID: 37463267
[TBL] [Abstract][Full Text] [Related]
20. SNAC for Enhanced Oral Bioavailability: An Updated Review.
Kommineni N; Sainaga Jyothi VGS; Butreddy A; Raju S; Shapira T; Khan W; Angsantikul P; Domb AJ
Pharm Res; 2023 Mar; 40(3):633-650. PubMed ID: 36539668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
